July 26, 2018 08:30 AM EDT
R&D

Now a three-time los­er, selume­tinib con­tin­ues to cause headaches as As­traZeneca dumps a failed PhI­II

John Carroll

Editor & Founder

Selume­tinib con­tin­ues to cause big headaches at As­traZeneca $AZN.

The MEK in­hibitor — now part­nered with Mer­ck $MRK in their big $8.5 bil­lion al­liance — failed a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

A service from the Financial Times